Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00901264 · ClinicalTrials.gov registry record
Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients
A clinical trial of Cancer, sponsored by Pierian Biosciences.
- Completed
- Registry status
- 300
- Enrollment target
- 11
- Study locations
NCT00901264: Completed study of Cancer, sponsored by Pierian Biosciences.
NCT00901264 is a study of Cancer that has completed, run by Pierian Biosciences. The registered enrollment target is 300 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00901264, a study of Cancer, has completed, sponsored by Pierian Biosciences.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.
Conditions Studied
Study Locations (11)
Tennessee
- DiaTech Oncology - Brentwood
- Cumberland Medical Center - Crossville
- Middle Tennessee Medical Center - Murfreesboro
- Baptist Hospital - Nashville
- Nashville Oncology Associates - Nashville
- St. Thomas Research Institute, LLC - Nashville
- Tennessee Breast Specialists - Nashville
- Tennessee Toracic Surgical Specialists - Nashville
California
- Wilshire Oncology Medical Group, Inc - La Verne
Florida
- Tampa General Hospital - Tampa
Quebec
- DiaTech Oncology - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-11 |
What the finished NCT00901264 record still lists
NCT00901264 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00901264 lists 11 locations in 4 states (Tennessee, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00901264 about?
NCT00901264 is a clinical study titled "Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients". The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.
What is the current status of trial NCT00901264?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2008-12. Estimated completion is 2012-11.
What conditions does trial NCT00901264 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT00901264?
This trial is sponsored by Pierian Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00901264 being conducted?
This trial has 11 study locations across California, Florida, Tennessee, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00901264's enrollment target sits among peer trials
300 179th of 615 higher than 428 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia